TUMOR ANGIOGENESIS IN ADVANCED-STAGE OVARIAN-CARCINOMA

被引:0
|
作者
HOLLINGSWORTH, HC
KOHN, EC
STEINBERG, SM
ROTHENBERG, ML
MERINO, MJ
机构
[1] NCI, PATHOL LAB, BETHESDA, MD 20892 USA
[2] NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD 20892 USA
[3] UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78229 USA
来源
AMERICAN JOURNAL OF PATHOLOGY | 1995年 / 147卷 / 01期
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tumor angiogenesis has been found to have prognostic significance in many tumor types for predicting an increased risk of metastasis. We assessed tumor vascularity in 43 cases of advanced stage (International Federation of Gynecologists and Obstetricians stages III and IV) ovarian cancer by using the highly specific endothelial cell marker CD34. Microvessel counts and stage were associated with disease-free survival and with overall survival by Kaplan-Meier analysis. The plots show that higher stage, higher average vessel count at 200 x (200 x avg) and 400 x (400 x avg) magnification and highest vessel count at 400 x (400 x high) magnification confer a worse prognosis for disease-free survival Average vessel count of less than 16(400 x avg, P-2 = 0.01) and less than 45 (200 x avg, P, = 0.026) suggested a better survival: Similarly, a high vessel count of less than 20 (400 x high, P-2 = 0.019) conferred a better survival as well. The plots suggest that higher stage, higher average vessel count at 200 x and 400 x, and highest vessel count at 200 x and 400 x show a trend to worse overall survival as well. With the Cox proportional hazards model, stage was the best predictor of overall survival, however, the average microvessel count at 400 x was found to be the best predictor of disease-free survival. These results suggest that analysis of neovascularization in advanced stage ovarian cancer may be a useful prognostic factor.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 50 条
  • [21] COMBINATION CHEMOTHERAPY OF ADVANCED OVARIAN-CARCINOMA
    KLEINMANNS, G
    DAUER, W
    KNIEF, JJ
    WESTERHAUSEN, M
    ONKOLOGIE, 1983, 6 (04): : 206 - 209
  • [22] CISPLATIN, CARBOPLATIN, AND CYCLOPHOSPHAMIDE COMBINATION CHEMOTHERAPY IN ADVANCED-STAGE OVARIAN-CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP PILOT-STUDY
    GREM, J
    ODWYER, P
    ELSON, P
    SIMON, N
    TRUMP, D
    FRONTIERA, M
    FALKSON, G
    VOGL, S
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) : 1793 - 1800
  • [23] The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
    Gorovetz, Michal
    Baekelandt, Mark
    Berner, Aasmund
    Trope, Claes G.
    Davidson, Ben
    Reich, Reuven
    GYNECOLOGIC ONCOLOGY, 2006, 103 (03) : 831 - 840
  • [24] The AP-2γ transcription factor is upregulated in advanced-stage ovarian carcinoma
    Odegaard, E
    Staff, AC
    Kærn, J
    Florenes, VA
    Kopolovic, J
    Tropé, CG
    Abeler, VM
    Reich, R
    Davidson, B
    GYNECOLOGIC ONCOLOGY, 2006, 100 (03) : 462 - 468
  • [25] Caveolin-1 expression in advanced-stage ovarian carcinoma - A clinicopathologic study
    Davidson, B
    Nesland, JM
    Goldberg, I
    Kopolovic, J
    Gotlieb, WH
    Byrne, M
    Ben-Baruch, G
    Berner, A
    Reich, R
    GYNECOLOGIC ONCOLOGY, 2001, 81 (02) : 166 - 171
  • [26] Sorafenib for advanced-stage hepatocellular carcinoma
    Tomuleasa, Ciprian
    Cristea, Victor
    Irimie, Alexandru
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (03) : 346 - 347
  • [27] Can advanced-stage ovarian cancer be cured?
    Steven Narod
    Nature Reviews Clinical Oncology, 2016, 13 : 255 - 261
  • [28] Can advanced-stage ovarian cancer be cured?
    Narod, Steven
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (04) : 255 - 261
  • [29] IMPLICATIONS OF AN OVERVIEW OF CHEMOTHERAPY IN ADVANCED OVARIAN-CARCINOMA
    WILLIAMS, CJ
    BRITISH JOURNAL OF CANCER, 1992, 66 (02) : 225 - 226